Welcome to our dedicated page for Abivax S.A. SEC filings (Ticker: ABVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abivax SA (ABVX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Abivax files reports such as Form 6-K and uses registration statements including Form F-3 and Form S-8 in connection with its capital markets activities. These documents offer insight into Abivax’s clinical progress, financing transactions, and other material developments as it advances obefazimod (ABX464) for chronic inflammatory diseases.
Through its Form 6-K current reports, Abivax has disclosed items such as an underwriting agreement for a public offering of American Depositary Shares under an automatic shelf registration statement on Form F-3, as well as information on major ordinary share transactions and financing arrangements. Filings also reference the company’s universal registration document with the French Autorité des Marchés Financiers and its Annual Report on Form 20-F, which includes a “Risk Factors” section describing key risks and uncertainties.
On this page, you can review real-time updates from EDGAR for Abivax’s U.S. filings, including current reports that discuss public offerings of ADSs, changes in financing structures, and significant clinical trial progress noted in the company’s tagged financial and narrative disclosures. Stock Titan’s tools provide AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand the implications of complex documents without reading every section.
In addition to capital markets information, Abivax’s filings can shed light on how the company allocates operating expenses to research and development for its ulcerative colitis and Crohn’s disease programs, as well as on changes in its financial position over time. Use this page to track new 6-K submissions, reference the registration statements that support securities offerings, and connect the company’s regulatory reporting with its clinical and corporate news flow.
Abivax SA reported interim results and updates through June 30, 2025 and subsequent events through August 2025. The company completed enrollment in its Phase 3 ABTECT program for ulcerative colitis on April 29, 2025 and announced positive July 22, 2025 induction results: the 50 mg once-daily dose met the FDA primary endpoint of clinical remission at Week 8 with placebo-adjusted rates of 19.3% (ABTECT-1, p<0.0001) and 13.4% (ABTECT-2, p=0.0001). For the six months ended June 30, 2025, R&D expenses rose to €77.9 million (up 21% vs prior year) driven by clinical progression; net financial loss was impacted by €6.9 million interest, €2.3 million FX losses and other non-cash items. Cash and cash equivalents were €60.9 million at June 30, 2025. A July 28, 2025 offering generated gross proceeds of €637.5 million (≈$747.5M) with estimated net proceeds ≈€597.2 million, which management expects, together with existing cash and note conversions, to fund operations into Q4 2027 and provide 12 months of runway after a planned NDA submission, assuming positive maintenance results. The statements were prepared on a going concern basis; shareholders' equity was negative at €48.3 million as of June 30, 2025. The company disclosed conversions of convertible instruments and potential material fair-value impacts in subsequent periods.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report joint beneficial ownership of 3,480,144 Abivax SA ordinary shares (represented by American Depository Shares), equal to 4.78% of the outstanding class. The filing shows 0 shares of sole voting or dispositive power and 3,480,144 shares of shared voting and dispositive power, with the percentage calculated from 72,784,660 ordinary shares outstanding per the issuer's disclosure.
The reporting persons state the securities were not acquired to change or influence control of the issuer (other than activities solely in connection with a nomination under applicable rules). The statement is filed jointly by the two Deep Track entities and David Kroin.